Ongoing trials with novel agents in early-stage and advanced-stage cHL
| Trial . | Clinical trials.gov identifier . | Clinical disease features . | Therapy received/arms of treatment . | Phase . | Anticipated enrollment . |
|---|---|---|---|---|---|
| Brentuximab vedotin and nivolumab in treating patients with early-stage cHL | NCT03712202 | Early stage (favorable, unfavorable, bulky, nonbulky) | ABVD × 2 → PET– 1. ABVD × 2→ nivo × 6 or 2. BV × nivo × 6 PET+ 3. BV-AVD × 4 → nivo × 6 *Bulky patients all randomized to arm 1 | 2 | 264 |
| Brentuximab vedotin in early-stage Hodgkin lymphoma (RADAR) | NCT04685616 | Early stage (favorable, unfavorable, bulky, nonbulky) | 1. ABVD ± ISRT ABVD × 2 → PET DS 1-3 ABVD × 2 DS 4 ABVD × 2 + ISRT DS 5 withdraw 2. BV-AVD ± ISRT BV-AVD × 2 → PET DS 1-3 BV-AVD × 1 DS 4 BV-AVD × 2 + ISRT DS 5 withdraw | 3 | 1042 |
| BV-AVD + nivolumab in stage I/II cHL | NCT03233347 | Early stage (favorable, unfavorable, nonbulky) | BV-AVD × 3 → PET 1. If PET+, → BV + nivo × 4 → If PET+, → nivo × 8 2. If PET–, → nivo × 8 | 2 | 82 |
| Avelumab + ABVD in advanced-stage cHL (AVENuE)50 | NCT03617666 | High risk stage II, stage II, stage IV cHL | Avelumab × 4 → ABVD × 2 → PET PET+, → escBEACOPP × 4 PET–, → AVD × 4 | 2 | 49 |
| Pembrolizumab and chemotherapy in advanced-stage cHL (KEYNOTE-C11) | NCT05008224 | Unfavorable risk stage I/II, stage III, or stage IV | Pembro × 3 → AVD × 2 → PET 1. PET–, → AVD × 4 → pembro × 4 2. PET + → escBEACOPP × 4 → pembro × 4 | 2 | 140 |
| Immunotherapy (nivolumab or BV) plus chemotherapy (S1826)35 | NCT03907488 | Stage III or IV cHL | 1. Nivolumab + AVD × 6 (with interim PET2) 2. BV-AVD × 6 (with interim PET2) | 3 | 987 |
| Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazne (AN + AD) for advanced-stage cHL (SGN35-027 Part B)50 | NCT03646123 | Bulky stage I/II, stage III, or stage IV | (BV + nivolumab + doxorubicin + dacarbazine) × 6 | 2 | 240 |
| Trial . | Clinical trials.gov identifier . | Clinical disease features . | Therapy received/arms of treatment . | Phase . | Anticipated enrollment . |
|---|---|---|---|---|---|
| Brentuximab vedotin and nivolumab in treating patients with early-stage cHL | NCT03712202 | Early stage (favorable, unfavorable, bulky, nonbulky) | ABVD × 2 → PET– 1. ABVD × 2→ nivo × 6 or 2. BV × nivo × 6 PET+ 3. BV-AVD × 4 → nivo × 6 *Bulky patients all randomized to arm 1 | 2 | 264 |
| Brentuximab vedotin in early-stage Hodgkin lymphoma (RADAR) | NCT04685616 | Early stage (favorable, unfavorable, bulky, nonbulky) | 1. ABVD ± ISRT ABVD × 2 → PET DS 1-3 ABVD × 2 DS 4 ABVD × 2 + ISRT DS 5 withdraw 2. BV-AVD ± ISRT BV-AVD × 2 → PET DS 1-3 BV-AVD × 1 DS 4 BV-AVD × 2 + ISRT DS 5 withdraw | 3 | 1042 |
| BV-AVD + nivolumab in stage I/II cHL | NCT03233347 | Early stage (favorable, unfavorable, nonbulky) | BV-AVD × 3 → PET 1. If PET+, → BV + nivo × 4 → If PET+, → nivo × 8 2. If PET–, → nivo × 8 | 2 | 82 |
| Avelumab + ABVD in advanced-stage cHL (AVENuE)50 | NCT03617666 | High risk stage II, stage II, stage IV cHL | Avelumab × 4 → ABVD × 2 → PET PET+, → escBEACOPP × 4 PET–, → AVD × 4 | 2 | 49 |
| Pembrolizumab and chemotherapy in advanced-stage cHL (KEYNOTE-C11) | NCT05008224 | Unfavorable risk stage I/II, stage III, or stage IV | Pembro × 3 → AVD × 2 → PET 1. PET–, → AVD × 4 → pembro × 4 2. PET + → escBEACOPP × 4 → pembro × 4 | 2 | 140 |
| Immunotherapy (nivolumab or BV) plus chemotherapy (S1826)35 | NCT03907488 | Stage III or IV cHL | 1. Nivolumab + AVD × 6 (with interim PET2) 2. BV-AVD × 6 (with interim PET2) | 3 | 987 |
| Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazne (AN + AD) for advanced-stage cHL (SGN35-027 Part B)50 | NCT03646123 | Bulky stage I/II, stage III, or stage IV | (BV + nivolumab + doxorubicin + dacarbazine) × 6 | 2 | 240 |